Published in Gastroenterology on September 01, 2006
Aspirin use and survival after diagnosis of colorectal cancer. JAMA (2009) 6.93
Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res (Phila) (2008) 5.82
Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut (2010) 4.01
Primary prevention of colorectal cancer. Gastroenterology (2010) 3.20
The role of aspirin in cancer prevention. Nat Rev Clin Oncol (2012) 2.94
The chromosomal instability pathway in colon cancer. Gastroenterology (2010) 2.59
Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. Cancer Prev Res (Phila) (2009) 2.46
Aspirin in the chemoprevention of colorectal neoplasia: an overview. Cancer Prev Res (Phila) (2011) 2.03
Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer. Breast Cancer Res (2007) 2.03
Cancer and inflammation: promise for biologic therapy. J Immunother (2010) 1.72
Reversal of gene expression changes in the colorectal normal-adenoma pathway by NS398 selective COX2 inhibitor. Br J Cancer (2010) 1.51
Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward. Clin Cancer Res (2010) 1.44
Tumor cells and tumor-associated macrophages: secreted proteins as potential targets for therapy. Clin Dev Immunol (2011) 1.41
Molecular targets for cancer chemoprevention. Nat Rev Drug Discov (2009) 1.38
Genetics and Genetic Biomarkers in Sporadic Colorectal Cancer. Gastroenterology (2015) 1.35
Regulation of inflammation in cancer by eicosanoids. Prostaglandins Other Lipid Mediat (2011) 1.31
Aspirin and COX-2 inhibitor use in patients with stage III colon cancer. J Natl Cancer Inst (2014) 1.28
GT-094, a NO-NSAID, inhibits colon cancer cell growth by activation of a reactive oxygen species-microRNA-27a: ZBTB10-specificity protein pathway. Mol Cancer Res (2010) 1.28
Aspirin as adjuvant therapy for colorectal cancer--reinterpreting paradigms. Nat Rev Clin Oncol (2012) 1.26
Prediagnostic non-steroidal anti-inflammatory drug use and survival after diagnosis of colorectal cancer. Gut (2010) 1.20
Chemoprevention in familial adenomatous polyposis. Best Pract Res Clin Gastroenterol (2011) 1.17
Biological activity of celecoxib in the bronchial epithelium of current and former smokers. Cancer Prev Res (Phila) (2010) 1.15
Much of the genetic risk of colorectal cancer is likely to be mediated through susceptibility to adenomas. Gastroenterology (2012) 1.15
Diet and prostate cancer: mechanisms of action and implications for chemoprevention. Nat Rev Urol (2010) 1.14
Targeted therapy for breast cancer prevention. Front Oncol (2013) 1.12
Primary and secondary prevention of colorectal cancer. Clin Med Insights Gastroenterol (2014) 1.07
Targeting polyamines and inflammation for cancer prevention. Recent Results Cancer Res (2011) 1.06
Nonsteroidal anti-inflammatory drug use after 3 years of aspirin use and colorectal adenoma risk: observational follow-up of a randomized study. J Natl Cancer Inst (2009) 1.05
Use of nonsteroidal antiinflammatory agents and incidence of ovarian cancer in 2 large prospective cohorts. Am J Epidemiol (2009) 1.05
A review of gene-drug interactions for nonsteroidal anti-inflammatory drug use in preventing colorectal neoplasia. Pharmacogenomics J (2008) 1.04
Association between nonsteroidal anti-inflammatory drug use and cutaneous squamous cell carcinoma. Arch Dermatol (2010) 1.03
Ibuprofen inhibits activation of nuclear {beta}-catenin in human colon adenomas and induces the phosphorylation of GSK-3{beta}. Cancer Prev Res (Phila) (2011) 1.00
Case-control study of aspirin use and risk of pancreatic cancer. Cancer Epidemiol Biomarkers Prev (2014) 1.00
Epoxyeicosatrienoic acids and soluble epoxide hydrolase: potential therapeutic targets for inflammation and its induced carcinogenesis. Am J Transl Res (2010) 0.98
Non-steroidal anti-inflammatory drugs and pancreatic cancer risk: a nested case-control study. Br J Cancer (2010) 0.98
Beyond standard adjuvant therapy for colon cancer: role of nonstandard interventions. Semin Oncol (2011) 0.97
NSAIDs and colorectal cancer prevention. J Gastroenterol (2009) 0.96
Rebamipide has the potential to reduce the intensity of NSAID-induced small intestinal injury: a double-blind, randomized, controlled trial evaluated by capsule endoscopy. J Gastroenterol (2010) 0.94
Prevention of NSAID-related upper gastrointestinal toxicity: a meta-analysis of traditional NSAIDs with gastroprotection and COX-2 inhibitors. Drug Healthc Patient Saf (2009) 0.94
DNA damage drives an activin a-dependent induction of cyclooxygenase-2 in premalignant cells and lesions. Cancer Prev Res (Phila) (2009) 0.93
Highly purified eicosapentaenoic acid as free fatty acids strongly suppresses polyps in Apc(Min/+) mice. Clin Cancer Res (2010) 0.92
Cyclooxygenase-2 polymorphisms, aspirin treatment, and risk for colorectal adenoma recurrence--data from a randomized clinical trial. Cancer Epidemiol Biomarkers Prev (2009) 0.92
A randomised controlled phase II trial of pre-operative celecoxib treatment reveals anti-tumour transcriptional response in primary breast cancer. Breast Cancer Res (2013) 0.92
Proneoplastic effects of PGE2 mediated by EP4 receptor in colorectal cancer. BMC Cancer (2009) 0.91
Nanoformulation of natural products for prevention and therapy of prostate cancer. Cancer Lett (2012) 0.90
Colorectal Chemoprevention Pilot Study (SWOG-9041), randomized and placebo controlled: the importance of multiple luminal lesions. Clin Colorectal Cancer (2011) 0.90
Potential targets for colorectal cancer prevention. Int J Mol Sci (2013) 0.89
Preclinical predictors of anticancer drug efficacy: critical assessment with emphasis on whether nanomolar potency should be required of candidate agents. J Pharmacol Exp Ther (2012) 0.87
Polyethylene glycol-mediated colorectal cancer chemoprevention: roles of epidermal growth factor receptor and Snail. Mol Cancer Ther (2008) 0.87
Designing an intervention to help people with colorectal adenomas reduce their intake of red and processed meat and increase their levels of physical activity: a qualitative study. BMC Cancer (2012) 0.87
Microsomal prostaglandin E synthase-1 promotes hepatocarcinogenesis through activation of a novel EGR1/β-catenin signaling axis. Oncogene (2011) 0.87
Postoperative nonsteroidal anti-inflammatory drugs and risk of anastomotic leak: meta-analysis of clinical and experimental studies. World J Surg (2014) 0.86
The association between NSAID use and colorectal cancer mortality: results from the women's health initiative. Cancer Epidemiol Biomarkers Prev (2012) 0.86
Regulation of the apoptosis-inducing kinase DRAK2 by cyclooxygenase-2 in colorectal cancer. Br J Cancer (2009) 0.86
Primary prevention of colorectal cancer: myth or reality? World J Gastroenterol (2014) 0.86
A study of prostaglandin pathway genes and interactions with current nonsteroidal anti-inflammatory drug use in colorectal adenoma. Cancer Prev Res (Phila) (2012) 0.86
Sulindac activates NF-κB signaling in colon cancer cells. Cell Commun Signal (2013) 0.85
Microsomal prostaglandin E synthase-1 inhibits PTEN and promotes experimental cholangiocarcinogenesis and tumor progression. Gastroenterology (2011) 0.84
Phytochemicals and colorectal cancer prevention--myth or reality? Nat Rev Gastroenterol Hepatol (2011) 0.84
Comparative bioavailability of sulindac in capsule and tablet formulations. Cancer Epidemiol Biomarkers Prev (2008) 0.83
The role of chemoprevention by selective cyclooxygenase-2 inhibitors in colorectal cancer patients - a population-based study. BMC Cancer (2012) 0.83
Colonic 15-PGDH levels are stable across distance and time and are not perturbed by aspirin intervention. Dig Dis Sci (2013) 0.83
New NSAID targets and derivatives for colorectal cancer chemoprevention. Recent Results Cancer Res (2013) 0.83
Genetic variation in inflammatory pathways is related to colorectal cancer survival. Clin Cancer Res (2011) 0.83
C-reactive protein genotypes and haplotypes, polymorphisms in NSAID-metabolizing enzymes, and risk of colorectal polyps. Pharmacogenet Genomics (2009) 0.83
Time-serial Assessment of Drug Combination Interventions in a Mouse Model of Colorectal Carcinogenesis Using Optical Coherence Tomography. Cancer Growth Metastasis (2015) 0.82
Chemopreventive doses of resveratrol do not produce cardiotoxicity in a rodent model of hepatocellular carcinoma. Invest New Drugs (2009) 0.82
15-PGDH inhibits hepatocellular carcinoma growth through 15-keto-PGE2/PPARγ-mediated activation of p21WAF1/Cip1. Oncogene (2013) 0.82
Cyclooxygenase- and lipoxygenase-mediated DNA damage. Cancer Metastasis Rev (2011) 0.82
Evaluation of pro-inflammatory markers plasma C-reactive protein and urinary prostaglandin-E2 metabolite in colorectal adenoma risk. Mol Carcinog (2015) 0.82
Nonsteroidal anti-inflammatory drug use and risk of adenomatous and hyperplastic polyps. Cancer Prev Res (Phila) (2011) 0.81
Increased cyclooxygenase-2 expression in juvenile polyposis syndrome. Clin Gastroenterol Hepatol (2008) 0.81
Impact of genetic polymorphisms on adenoma recurrence and toxicity in a COX2 inhibitor (celecoxib) trial: results from a pilot study. Pharmacogenet Genomics (2013) 0.81
Genetic deletion of microsomal prostaglandin E synthase-1 suppresses mouse mammary tumor growth and angiogenesis. Prostaglandins Other Lipid Mediat (2013) 0.81
Colorectal cancer chemoprevention: is this the future of colorectal cancer prevention? ScientificWorldJournal (2012) 0.81
CG100649, a novel COX-2 inhibitor, inhibits colorectal adenoma and carcinoma growth in mouse models. Invest New Drugs (2014) 0.81
Design and baseline characteristics of participants in a phase III randomized trial of celecoxib and selenium for colorectal adenoma prevention. Cancer Prev Res (Phila) (2012) 0.81
The relationship between cancer and rheumatoid arthritis: still a large research agenda. Arthritis Res Ther (2008) 0.80
Chemoprevention with special reference to inherited colorectal cancer. Fam Cancer (2007) 0.80
New insights into the molecular pathogenesis of colorectal cancer. Drug Discov Today Dis Mech (2006) 0.80
The proapoptotic effect of traditional and novel nonsteroidal anti-inflammatory drugs in mammalian and yeast cells. Oxid Med Cell Longev (2013) 0.80
The EP1 receptor for prostaglandin E2 promotes the development and progression of malignant murine skin tumors. Mol Carcinog (2011) 0.80
A novel sulindac derivative lacking cyclooxygenase-inhibitory activities suppresses carcinogenesis in the transgenic adenocarcinoma of mouse prostate model. Cancer Prev Res (Phila) (2010) 0.80
COX-2 modulates mammary tumor progression in response to collagen density. Breast Cancer Res (2016) 0.80
Aspirin and familial adenomatous polyposis: coming full circle. Cancer Prev Res (Phila) (2011) 0.80
Understanding the molecular mechanisms of cancer prevention by dietary phytochemicals: From experimental models to clinical trials. World J Biol Chem (2016) 0.79
Polymorphic human prostaglandin H synthase-2 proteins and their interactions with cyclooxygenase substrates and inhibitors. Pharmacogenomics J (2010) 0.79
Enhancing adherence in trials promoting change in diet and physical activity in individuals with a diagnosis of colorectal adenoma; a systematic review of behavioural intervention approaches. BMC Cancer (2015) 0.79
Is the demonstration of adenoma reduction with rofecoxib a pyrrhic victory? Gastroenterology (2006) 0.78
Genetic variation in prostaglandin synthesis and related pathways, NSAID use and colorectal cancer risk in the Colon Cancer Family Registry. Carcinogenesis (2014) 0.77
Omega-3 Polyunsaturated Fatty Acids Upregulate 15-PGDH Expression in Cholangiocarcinoma Cells by Inhibiting miR-26a/b Expression. Cancer Res (2015) 0.77
Clinical end points for developing pharmaceuticals to manage patients with a sporadic or genetic risk of colorectal cancer. Expert Rev Gastroenterol Hepatol (2012) 0.76
Candidate cancer-targeting agents identified by expression-profiling arrays. Onco Targets Ther (2013) 0.76
Effects of supplemental vitamin D and calcium on normal colon tissue and circulating biomarkers of risk for colorectal neoplasms. J Steroid Biochem Mol Biol (2015) 0.76
Quantitation of celecoxib and four of its metabolites in rat blood by UPLC-MS/MS clarifies their blood distribution patterns and provides more accurate pharmacokinetics profiles. J Chromatogr B Analyt Technol Biomed Life Sci (2015) 0.76
Prostaglandins induce early growth response 1 transcription factor mediated microsomal prostaglandin E2 synthase up-regulation for colorectal cancer progression. Oncotarget (2015) 0.76
Role of the Aryl Hydrocarbon Receptor in Colon Neoplasia. Cancers (Basel) (2015) 0.76
Consensus on the Prevention, Screening, Early Diagnosis and Treatment of Colorectal Tumors in China: Chinese Society of Gastroenterology, October 14-15, 2011, Shanghai, China. Gastrointest Tumors (2014) 0.75
Marketed nonsteroidal anti-inflammatory agents, antihypertensives, and human immunodeficiency virus protease inhibitors: as-yet-unused weapons of the oncologists' arsenal. Ther Clin Risk Manag (2015) 0.75
Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med (2005) 15.46
A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med (2003) 9.18
Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. JAMA (2007) 7.93
Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med (2010) 7.39
Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology (2012) 7.15
Understanding cancer treatment and outcomes: the Cancer Care Outcomes Research and Surveillance Consortium. J Clin Oncol (2004) 7.02
A retrograde-viewing device improves detection of adenomas in the colon: a prospective efficacy evaluation (with videos). Gastrointest Endosc (2009) 5.38
Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet (2010) 5.05
Colorectal cancer in patients under close colonoscopic surveillance. Gastroenterology (2005) 4.31
Results of repeat sigmoidoscopy 3 years after a negative examination. JAMA (2003) 3.82
Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults. Gastroenterology (2008) 3.79
Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology (2009) 3.73
Vitamin D, calcium supplementation, and colorectal adenomas: results of a randomized trial. J Natl Cancer Inst (2003) 3.44
Clinical practice. Screening for colorectal cancer. N Engl J Med (2002) 3.43
Constipation and a low-fiber diet are not associated with diverticulosis. Clin Gastroenterol Hepatol (2013) 3.31
Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst (2009) 3.15
A high-fiber diet does not protect against asymptomatic diverticulosis. Gastroenterology (2011) 3.03
Variability in diagnostic criteria for eosinophilic esophagitis: a systematic review. Am J Gastroenterol (2007) 2.94
The burden of gastrointestinal and liver diseases, 2006. Am J Gastroenterol (2006) 2.93
A Trial of Calcium and Vitamin D for the Prevention of Colorectal Adenomas. N Engl J Med (2015) 2.88
Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. Lancet (2008) 2.83
Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol (2010) 2.80
A population-based cohort study comparing laparoscopic cholecystectomy and open cholecystectomy. Am J Gastroenterol (2002) 2.75
Molecular characterization of mucosal adherent bacteria and associations with colorectal adenomas. Gut Microbes (2010) 2.70
Folic acid and risk of prostate cancer: results from a randomized clinical trial. J Natl Cancer Inst (2009) 2.64
Mucins and mucin binding proteins in colorectal cancer. Cancer Metastasis Rev (2004) 2.64
A germline variant in the TP53 polyadenylation signal confers cancer susceptibility. Nat Genet (2011) 2.43
Flexible sigmoidoscopy in the PLCO cancer screening trial: results from the baseline screening examination of a randomized trial. J Natl Cancer Inst (2005) 2.27
RNA expression analysis of formalin-fixed paraffin-embedded tumors. Lab Invest (2007) 2.25
Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. Clin Cancer Res (2006) 2.24
Low-dose aspirin and cancer mortality: a meta-analysis of randomized trials. Am J Med (2012) 2.23
Development of an internet-based cohort of patients with inflammatory bowel diseases (CCFA Partners): methodology and initial results. Inflamm Bowel Dis (2012) 2.23
KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer. Mol Cancer Ther (2009) 2.22
The Wnt antagonist sFRP1 in colorectal tumorigenesis. Cancer Res (2004) 2.16
Digestive and liver diseases statistics, 2004. Gastroenterology (2004) 2.14
A causal association between isotretinoin and inflammatory bowel disease has yet to be established. Am J Gastroenterol (2009) 2.14
Circulating levels of inflammatory cytokines and risk of colorectal adenomas. Cancer Res (2008) 2.13
Isotretinoin use and the risk of inflammatory bowel disease: a case-control study. Am J Gastroenterol (2010) 2.10
Associations of total energy and macronutrients with colon cancer risk in African Americans and Whites: results from the North Carolina colon cancer study. Am J Epidemiol (2003) 2.06
[Current management of nonvariceal upper gastrointestinal bleeding in Spain]. Gastroenterol Hepatol (2012) 2.04
Fusobacterium is associated with colorectal adenomas. PLoS One (2013) 1.99
Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. Am J Gastroenterol (2008) 1.99
Mice deficient for the vesicular acetylcholine transporter are myasthenic and have deficits in object and social recognition. Neuron (2006) 1.98
Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology (2012) 1.97
Gastric cancer susceptibility is not linked to pro-and anti-inflammatory cytokine gene polymorphisms in whites: a Nationwide Multicenter Study in Spain. Am J Gastroenterol (2007) 1.92
Global DNA hypomethylation (LINE-1) in the normal colon and lifestyle characteristics and dietary and genetic factors. Cancer Epidemiol Biomarkers Prev (2009) 1.88
Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability. Pediatr Blood Cancer (2009) 1.83
Sleep disturbance and risk of active disease in patients with Crohn's disease and ulcerative colitis. Clin Gastroenterol Hepatol (2013) 1.83
A novel composite endpoint to evaluate the gastrointestinal (GI) effects of nonsteroidal antiinflammatory drugs through the entire GI tract. J Rheumatol (2009) 1.81
Association between hemochromatosis (HFE) gene mutation carrier status and the risk of colon cancer. J Natl Cancer Inst (2003) 1.80
Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial. Gastroenterology (2004) 1.79
Patient time requirements for screening colonoscopy. Am J Gastroenterol (2007) 1.74
Prolonged effect of calcium supplementation on risk of colorectal adenomas in a randomized trial. J Natl Cancer Inst (2007) 1.73
Editorial: colonoscopy and colorectal cancer mortality: strong beliefs or strong facts? Am J Gastroenterol (2010) 1.71
Characteristics and survival of interval and sporadic colorectal cancer patients: a nationwide population-based cohort study. Am J Gastroenterol (2013) 1.71
Suboptimal rates of cervical testing among women with inflammatory bowel disease. Clin Gastroenterol Hepatol (2008) 1.71
Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial. Gastroenterology (2003) 1.70
Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study. Gut (2011) 1.70
Loss of activin receptor type 2 protein expression in microsatellite unstable colon cancers. Gastroenterology (2004) 1.70
Chronic stress induces mast cell-dependent bacterial adherence and initiates mucosal inflammation in rat intestine. Gastroenterology (2002) 1.68
Determinants of medical system delay in the diagnosis of colorectal cancer within the Veteran Affairs Health System. Dig Dis Sci (2010) 1.68
Effect of calcium supplementation on the risk of large bowel polyps. J Natl Cancer Inst (2004) 1.67
Reduced polyp detection as endoscopy shift progresses: experience with screening colonoscopy at a tertiary-care hospital. J Clin Gastroenterol (2011) 1.66
Microsatellite instability and DNA mismatch repair protein deficiency in Lynch syndrome colorectal polyps. Cancer Prev Res (Phila) (2012) 1.65
Aminoaciduria and altered renal expression of luminal amino acid transporters in mice lacking novel gene collectrin. Am J Physiol Renal Physiol (2006) 1.63
Nuclear export of phosphorylated galectin-3 regulates its antiapoptotic activity in response to chemotherapeutic drugs. Mol Cell Biol (2004) 1.63
Gastrointestinal stromal tumours: consensus statement on diagnosis and treatment. Can J Gastroenterol (2006) 1.62
Increased rectal microbial richness is associated with the presence of colorectal adenomas in humans. ISME J (2012) 1.62
Low-dose aspirin affects the small bowel mucosa: results of a pilot study with a multidimensional assessment. Clin Gastroenterol Hepatol (2008) 1.62
Risk of cancer in cases of suspected lynch syndrome without germline mutation. Gastroenterology (2013) 1.55
Insulin resistance, apoptosis, and colorectal adenoma risk. Cancer Epidemiol Biomarkers Prev (2005) 1.52
Donor morbidity associated with right lobectomy for living donor liver transplantation to adult recipients: a systematic review. Liver Transpl (2002) 1.52
Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract. Best Pract Res Clin Gastroenterol (2010) 1.51
Recognition and treatment of irritable bowel syndrome among women with chronic pelvic pain. Am J Obstet Gynecol (2005) 1.49
Risk factors for advanced colorectal adenomas: a pooled analysis. Cancer Epidemiol Biomarkers Prev (2002) 1.48
Relationship of EMAST and microsatellite instability among patients with rectal cancer. J Gastrointest Surg (2010) 1.48
Risk of advanced proximal neoplasms according to distal colorectal findings: comparison of sigmoidoscopy-based strategies. J Natl Cancer Inst (2013) 1.47
Role of Nonsteroidal Anti-Inflammatory Drugs in Exacerbations of Inflammatory Bowel Disease. J Clin Gastroenterol (2016) 1.47
Chromoendoscopy detects more adenomas than colonoscopy using intensive inspection without dye spraying. Cancer Prev Res (Phila) (2008) 1.47
Diet, lifestyle, and genomic instability in the North Carolina Colon Cancer Study. Cancer Epidemiol Biomarkers Prev (2005) 1.45
Neutrophil gelatinase-associated lipocalin: a novel suppressor of invasion and angiogenesis in pancreatic cancer. Cancer Res (2008) 1.45
Value of patient time invested in the colonoscopy screening process: time requirements for colonoscopy study. Med Decis Making (2008) 1.45
Longitudinal changes in lifestyle behaviors and health status in colon cancer survivors. Cancer Epidemiol Biomarkers Prev (2004) 1.45